[go: up one dir, main page]

PE20001109A1 - Derivados de rivabirina - Google Patents

Derivados de rivabirina

Info

Publication number
PE20001109A1
PE20001109A1 PE1999001034A PE00103499A PE20001109A1 PE 20001109 A1 PE20001109 A1 PE 20001109A1 PE 1999001034 A PE1999001034 A PE 1999001034A PE 00103499 A PE00103499 A PE 00103499A PE 20001109 A1 PE20001109 A1 PE 20001109A1
Authority
PE
Peru
Prior art keywords
chr7a
rivabirin
derivatives
or7b
nr7ar7b
Prior art date
Application number
PE1999001034A
Other languages
English (en)
Inventor
Raymond G Lovey
Anil K Saksena
Viyyoor M Girijavallabhan
Ashit K Ganguly
Jinping Mccormick
Frank Bennett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20001109A1 publication Critical patent/PE20001109A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE AL USO DE a)DERIVADOS DE RIVABIRINA DE FORMULA I, DONDE POR LO MENOS UNO DE R2, R3 o R5 ES H; R6-(W)x-CO-; R6-(W)x-CS-(OH)2PO-R6-(W)x-PO(OH)-; Y AL MENOS UNO DE R2, R3 o R5 NO ES H; R6 ES H, ALQUILO, ALCANOILO, CICLOALQUILO, HETEROCICLO, ARILO, NR7aR7b, -(CHR7a)e-(CH2)f-CO-OR7b, -(CHR7a)e-(CH2)f-OR7b, (CH2R7a)e-(CH2)f-NR7aR7b; W ES NR18, S; R7a ES H, ALQUILO, ARILO, ALCANOILO; O R7a Y R7b JUNTO CON N, CHR7a, NR7b, O, S, SO, SO2 FORMAN UN ANILLO DE 5-7 MIEMBROS; e ES 0-6; f ES 0-10; x ES 0-1; UTILIZANDOSE DE 1 mg/Kg POR DIA A 100 mg/Kg POR DIA; b)INTERFERON ALFA SELECCIONANDOSE DE IF-O-2a, IF-O-2b, IF-O-PURIFICADO, IF-O-PEGILADO, UTILIZANDOSE 2-10 MILLONES DE UNIDADES POR SEMANA. LA COMBINACION PUEDE SER USADA DE 20 A 50 SEMANAS PARA PODER ERRADICAR HCV-RNA POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA INFECCION POR HEPATITIS C CRONICA (HCV)
PE1999001034A 1998-10-16 1999-10-14 Derivados de rivabirina PE20001109A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
PE20001109A1 true PE20001109A1 (es) 2000-10-28

Family

ID=22634639

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001034A PE20001109A1 (es) 1998-10-16 1999-10-14 Derivados de rivabirina

Country Status (9)

Country Link
US (1) US6277830B1 (es)
EP (1) EP1121370A1 (es)
KR (1) KR20010080098A (es)
AR (1) AR021226A1 (es)
AU (1) AU1197600A (es)
CO (1) CO5160265A1 (es)
PE (1) PE20001109A1 (es)
WO (1) WO2000023455A1 (es)
ZA (1) ZA200102917B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800616B2 (en) * 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
SI20976A (sl) * 1999-12-23 2003-02-28 Icn Pharmaceuticals, Inc. Sestavki in postopki za L-nukleozide, L-nukleotide in njihove analoge
WO2001066132A2 (en) * 2000-03-09 2001-09-13 Schering Corporation Hiv immune adjuvant therapy
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA007867B1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
US6510314B1 (en) 2000-09-08 2003-01-21 Visteon Global Technologies, Inc. Mixer circuit with output stage for implementation on integrated circuit
CN1516599A (zh) * 2000-10-18 2004-07-28 ���鹫˾ 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2003000713A1 (en) * 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
AU2003257285A1 (en) * 2002-07-25 2004-02-16 Micrologix Biotech Inc. Inhibitors of rna dependent rna polymerase and uses thereof
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
EP1572710A2 (en) * 2002-12-10 2005-09-14 F. Hoffmann-La Roche Ag Antiviral nucleoside derivatives
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
CL2004001161A1 (es) * 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
CA2537849A1 (en) * 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Process for preparing antiviral nucleoside derivatives
WO2005023826A2 (en) * 2003-09-11 2005-03-17 F.Hoffmann-La Roche Ag Polymorphic nucleoside compounds
ES2398912T3 (es) 2003-10-14 2013-03-22 F. Hoffmann-La Roche Ltd. Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US20060018875A1 (en) * 2004-06-14 2006-01-26 Blatt Lawrence M Interferon compositions and methods of use thereof
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) * 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
JP2008540425A (ja) * 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2054076A2 (en) * 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
MX2009002707A (es) * 2006-09-11 2009-11-26 Southern Res Inst Nucleosidos de azoles y su utilizacion como inhibidores de arn y adn polimerasas virales.
WO2008052722A2 (en) * 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug
BRPI0811020A2 (pt) 2007-05-03 2015-07-21 Intermune Inc Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral.
CA2686546A1 (en) * 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
KR20110075019A (ko) 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
CA2775697A1 (en) 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
CN103228278A (zh) 2010-09-30 2013-07-31 贝林格尔.英格海姆国际有限公司 治疗hcv感染的组合疗法
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US9364484B2 (en) 2011-12-06 2016-06-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
GB1482736A (en) 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US4925930A (en) 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
RU2129437C1 (ru) * 1992-02-10 1999-04-27 Интерферон Сайнс Инк. Композиция альфа-интерферона и способ ее получения из лейкоцитов крови человека
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
AU735438B2 (en) 1996-11-12 2001-07-05 Medivir Ab Nucleosides

Also Published As

Publication number Publication date
US6277830B1 (en) 2001-08-21
EP1121370A1 (en) 2001-08-08
CO5160265A1 (es) 2002-05-30
KR20010080098A (ko) 2001-08-22
WO2000023455A9 (en) 2000-08-24
AU1197600A (en) 2000-05-08
ZA200102917B (en) 2002-07-09
AR021226A1 (es) 2002-07-03
WO2000023455A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
PE20001109A1 (es) Derivados de rivabirina
PE20001369A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa pegilado
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
ES2174992T3 (es) Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
MD1224C2 (ro) Utilizare a analogilor nucleozidici cu 1,3-oxatiolan în tratamentul hepatitei B
ES2085862T3 (es) Composicion de detergente.
EP0491864A4 (en) Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
NO20093217L (no) Makrocykliske analoger og fremgangsmater for fremstilling og anvendelse derav
CL2003002756A1 (es) Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
NZ307089A (en) Alpha substituted pyrimidine thioalkyl and alkylether compounds and medicaments
DK0563093T4 (da) Præparat anvendt som terapeutisk middel mod kroniske virale hepatitissygdomme
GB8617482D0 (en) Pharmaceutical composition
AU5670690A (en) Lysolecithin derivatives for treating autoimmune diseases
DK288686A (da) Farmaceutiske praeparater
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES8506622A1 (es) Procedimiento para preparar analogos de mevalono-lactona y derivados de los mismos
IT1251838B (it) Uso della nimesulide nel trattamento della cataratta
WO1993003058A3 (en) Non-desensitizing analogs of gnrh and other biologically active ligands
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
PT1115420E (pt) Tratamento de infeccao de hepatite b com timosina alfa 1 e lamivudine
MY111439A (en) Thymosin alpha 1 derivatives
KR910019621A (ko) 상승병용을 이용한 안고혈압 치료
DK0430551T3 (da) Behandling af hjertedysfunktion med 15-keto-prostaglandinforbindelser

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed